Map Parkinson progression in carriers
- Trial ID
- NCT03523104
- Official Title
- The Chinese Parkinson's Disease With LRRK2 Variants Registry
- Goal
- Map Parkinson progression in carriers
- Status
- RECRUITING
- Sponsor
- Xiangya Hospital of Central South University
- Study Type
- OBSERVATIONAL
- Enrollment
- 1000 participants
- Conditions
- Parkinson Disease
Summary For Families
The goal is to map how Parkinson's linked to changes in the LRRK2 gene presents and progresses, so researchers can better understand symptoms, progression, and treatment responses in this genetic subgroup. The project is an observational registry that collects medical history, genetic test results, and follow-up clinical data rather than testing a treatment, building a large dataset to study genotype-phenotype links and the natural history of LRRK2-associated PD. Enrollment is open in China to people diagnosed with Parkinson's who have a confirmed LRRK2 variant, the registry plans about 1,000 participants, and no age or sex limits are listed.
Locations
- Xiangya Hospital of Central South University, Changsha, Hunan, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to map how Parkinson's linked to changes in the LRRK2 gene presents and progresses, so researchers can better understand symptoms, progression, and treatment responses in this genetic subgroup. The project is an observational registry that collects medical history, genetic test results, and follow-up clinical data rather than testing a treatment, building a large dataset to study genotype-phenotype links and the natural history of LRRK2-associated PD. Enrollment is open in China to people diagnosed with Parkinson's who have a confirmed LRRK2 variant, the registry plans about 1,000 participants, and no age or sex limits are listed.
- Who can participate?
- Eligibility criteria vary. Check the full listing on ClinicalTrials.gov for detailed inclusion and exclusion criteria.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 10 years.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.